Abstract PTH-018 Table 1
POOLED
No. studiesNo. lesionsNo. neoplasia (%)Sensitivity (95% CI)+I2 Specificity (95% CI)+I2 +LHR (95% CI)+I2 -LHR (95% CI)+I2 DOR (95% CI)+I2 AUROC (SEAUC) Q
DCE61767 249 (14%)0.558
(0.49–0.62)
I2=85.6%		0.89
(0.87–0.9)
I2=84.4% 		4.21
(2.27–7.8)
I2=86.7% 		0.48
(0.3–0.8)
I2=81.8% 		9.92
(3.7–26)
I2=80% 		0.838
(0.071)
0.76
VCE5987 121 (12.3%) 0.803
(0.7–0.87)
I2=78%		0.833
(0.8–0.86)
I2=95.4% 		5.331
(2.8–10.2)
I2=92.9% 		0.201
(0.06–0.6)
I2=87.2% 		28.21
(6.1–130)
I2=86.4% 		0.9137
(0.056)
0.84
Magnification522679 (13.3%) 0.899
(0.8–0.96)
I2=37.1% 		0.856
(0.8–0.89)
I2=44.9% 		6.55
(3.9–11)
I2=62.0% 		0.143
(0.06–0.3)
I2=35.6% 		53.01
(14-199)
I2=54.7% 		0.9304
(0.0251)
0.865
CLE81179 86 (7%)0.826
(0.7–0.89)
I2=60.6%		0.947
(0.9–0.95)
I2=83.4% 		13.11
(5.3–31)
I2=85.7 		0.20
(0.08–0.5)
I2=66.7%		78.1
(17-341)
I2=74.2% 		0.959
(0.031)
0.903
RT Kudo PP10 2724 357 (13%) 0.624
(0.5–0.76)
I2=88.2% 		0.88
(0.8–0.93)
I2=92.8% 		5.64
(3.52–9.1)
I2=90.1% 		0.34
(0.2–0.57)
I2=86.8%		20.0
(8–50.6)
I2=85.4%		0.917
(0.039)
0.85
RT CLE640247 (11.7%)0.872
(0.70–1.0)
I2=60.8% 		0.96
(0.9–0.99)
I2=41.3% 		15.4
(6.29–38)
I2=60.5% 		0.154
(0.03–0.6)
I2=71.1%		108.74
(21-552)
I2=54.2% 		0.97
(0.024)
0.92